Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liafensine in Treatment-Resistant Depression (DGM4-positive)
CTR20221896Phase 2Completed
- Sponsor
- Denovo Biopharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liafensine in major depressive disorder (MDD), sponsored by Denovo Biopharma. Started Jul 2022; status: completed.
02
Drugs
liafensine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20221896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221896.